Isolated Abducens Nerve Palsy Following Pembrolizumab
| Autor: | Alexander N. Shoushtari, David H. Abramson, Jasmine H. Francis, Korey Jaben |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Palsy
business.industry Immune checkpoint inhibitors Melanoma Pembrolizumab Case Reports medicine.disease Programmed Cell Death 1 Receptor Extraocular muscles 03 medical and health sciences Ophthalmology 0302 clinical medicine medicine.anatomical_structure 030221 ophthalmology & optometry Cancer research Medicine Neurology (clinical) business Abducens nerve 030217 neurology & neurosurgery |
| Zdroj: | Neuroophthalmology |
| Popis: | Pembrolizumab is a checkpoint inhibitor targeting the programmed cell death 1 receptor of lymphocytes and is used in the treatment of solid tumours including melanoma. The authors report a 64-year-old man treated with pembrolizumab for stage IV cutaneous melanoma (primary cutaneous melanoma of the right lower back) with liver metastases. The patient developed a horizontal binocular diplopia due to an isolated unilateral cranial nerve VI palsy. Following 1 week of high dose oral steroid therapy and cessation of the drug, the patient’s nerve palsy and associated diplopic symptoms improved dramatically, and after 6 weeks of oral steroid taper and drug cessation, the palsy resolved completely. Few reports of checkpoint inhibitor autoimmune-induced isolated cranial nerve palsies have been described, and this is the first report of drug-induced isolated cranial nerve VI palsy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|